Pomerantz Law Firm Issues Reminder to Ultragenyx Investors About Class Action Lawsuit and Deadlines

Investor Alert: Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

In a significant legal update, Pomerantz LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc., a key player in the biopharmaceutical industry. This lawsuit is aimed at protecting the interests of investors who have suffered financial losses due to alleged securities fraud and irregular business practices by the company.

Overview of the Lawsuit

The lawsuit points to certain actions taken by Ultragenyx and its executives that are believed to have misled investors regarding the company's financial status and future prospects. Investors are urged to take action, specifically to reach out to Pomerantz LLP by April 6, 2026, if they wish to be appointed as Lead Plaintiff in the case.

Key Developments

On July 9, 2025, Ultragenyx, together with its development partner Mereo BioPharma Group plc, declared that the Phase 3 clinical trials for its lead product UX143 (setrusumab) were not yielding the anticipated results. This news triggered a 25.11% decline in Ultragenyx’s stock price, dropping $10.41 per share, marking a clear warning sign for investors.

By December 29, 2025, the situation worsened when the firm reported that the Phase III Orbit and Cosmic Studies did not meet their primary endpoints. The announcement led to a staggering 42.32% drop in stock prices, compounding investor losses significantly.

Pomerantz LLP is committed to representing the interests of the investors adversely affected by these developments. They advise that anyone who acquired Ultragenyx securities during this tumultuous period should consider joining the class action to secure their rights.

Investor Involvement

Individuals interested in joining the lawsuit are encouraged to contact Danielle Peyton at Pomerantz LLP via email or phone. It's crucial that investors include necessary details such as their mailing address, phone number, and the number of shares acquired in their correspondences.

About Pomerantz LLP

With a storied history in class action litigation, Pomerantz LLP is recognized as a leader in corporate, securities, and antitrust law. Founded over 85 years ago, the firm has a proven track record of recovering substantial damages for victims of securities fraud and corporate misconduct, making it a trusted entity in investor advocacy. For more detailed information about the lawsuit and to download a copy of the complaint, investors can visit their official site at www.pomerantzlaw.com.

This situation underscores the importance of vigilance and proactive engagement from investors. As the market continues to fluctuate, ensuring protection against corporate misconduct has never been more critical. Stay informed, remain vigilant, and remember that taking early action can make all the difference in securing your financial future.